Table 1 Demographic and clinical characteristics of the study subjects
Variables | UC (N = 181) |
|---|---|
Sex | |
Male | 107 (59.1%) |
Age at UC diagnosis (years), median (IQR) | 35.8 (26.1–47.8) |
Age at FC level measurement (years), median (IQR) | 40.5 (29.2–53.8) |
Disease duration before FC level measurement (months), median (IQR) | 18.4 (1.9–59.5) |
Maximum extent of UC | |
Proctitis | 33 (18.2%) |
Left-sided colitis | 47 (26.0%) |
Extensive colitis | 101 (55.8%) |
Disease severity of UC | |
Clinical remission (Mayo score 0-2) | 17 (9.4%) |
Mild activity (Mayo score 3-5) | 48 (26.5%) |
Moderate activity (Mayo score 6-10) | 98 (54.1%) |
Severe activity (Mayo score 11-12) | 18 (10.0%) |
Smoking status at UC diagnosis | |
Never smoker | 100 (55.2%) |
Former smoker | 47 (26.0%) |
Current smoker | 34 (18.8%) |
Family history of IBD | |
No family history | 171 (94.5%) |
First-degree relative | 9 (5.0%) |
Second-degree relative | 1 (0.5%) |
History of medication use at FC level measurement | |
Oral 5-ASA | 154 (85.1%) |
Topical 5-ASA | 116 (64.1%) |
Topical steroids | 32 (17.7%) |
Systemic corticosteroids | 124 (68.5%) |
Thiopurines | 58 (32.0%) |
Cyclosporine | 4 (2.2%) |
Anti-TNF agents | 30 (16.6%) |
FC level (mg/kg), median (IQR) | 1518.0 (360.0–4205.0) |
Hematocrit value (%), median (IQR) | 37.7 (32.8–42.0) |
Serum albumin level (g/dL), median (IQR) | 3.7 (2.9–4.0) |
Erythrocyte sedimentation rate (mm/h), median (IQR) | 26.0 (11.5–44.5) |
White blood cell count (×103 /uL), median (IQR) | 7.1 (5.6–9.5) |
Platelet count (×103 /uL), median (IQR) | 300.0 (242.0–379.0) |
C-reactive protein level (mg/L), median (IQR) | 0.41 (0.10–2.37) |
Partial Mayo score, median (IQR) | 5 (2–6.5) |
Mayo endoscopic subscore, median (IQR) | 3 (2–3) |
Mayo score, median (IQR) | 6 (3–8) |
UCEIS, median (IQR) | 4 (3–6) |